Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 283-815-6 | CAS number: 84731-55-5
Endpoint summary
Administrative data
Description of key information
There are no data for lithium isooctadecanoate. However, data have been read across from fatty acids C18 (unsaturated) lithium salt. On this basis, it is considered that lithium isooctadecanoate would exhibit a lack of acute toxicity potential. There is no evidence of a relevant intrinsic acute toxicity requiring classification or substance specific RMMs.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
There are no data available for lithium isooctadecanoate but an acute oral toxicity study is currently ongoing.
Data have been read across from fatty acids C18 (unsaturated) lithium salts. This is considered to be an appropriate structural analogue on the basis that the two substances have common structures of a lithium salt of C18 fatty acids. Lithium isooctadecanoate has a single methyl branch while fatty acids C18 (unsaturated) lithium salts contains unsaturated carbon-carbon double bonds. The methyl branched fatty acid component of lithium isooctadecanoate is not expected to be hazardous. Therefore, read across of this data to lithium isooctadecanoate is considered appropriate. See IUCLID section 13 for read across justification.
Fatty acids C18 (unsaturated) lithium salts is a UVCB substance consisting of C18 fatty acids with a range of degrees of unsaturation. Although a molecular weight has not been specified, as a lithium salt of C18 fatty acids, the molecular weight is expected to be comparable to that of lithium isooctadecanoate, varying by only a few hydrogens. Therefore, no calculations have been applied to convert the toxicity values which have been read across between the substances.
Key acute toxicity studies in rats have been conducted on lithium salts of fatty acids C18 (unsaturated). The results from the studies showed no evidence of acute toxicity up to the highest doses tested (2000 mg/kg or greater). It is considered that lithium isooctadecanoate exhibits a similar lack of acute toxicity potential. There is no evidence of a relevant intrinsic acute toxicity requiring classification or substance specific RMMs.
Justification for classification or non-classification
The oral and dermal LD50 value of an appropriate read across substance is greater than 2000 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
